FROM THE EDITORS
Welcome to the HR+ HER2- Breast Cancer Resource Center! We’re excited to present you with current information, news items, highlights from the literature, and other resources that focus on this disease space and the advanced practitioner’s role in delivering high-quality care to patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.
![]() |
![]() |
Katie Newlin, RN, MSN, AGPCNP-BC Washington University in St. Louis/Siteman Cancer Center
|
Kate Taucher, PharmD, MHA, BCOP, FASHP, FAPO, FHOPA UCHealth Memorial Hospital |
Resources
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)
HER2 Testing in Breast Cancer - 2023 Guideline Update
Abemaciclib Clinical Management Guide
Real-world Risk of Recurrence by Nodal Status in Patients with HR+, HER2-, Node-positive, High-Risk Early Breast Cancer
Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update
News & Literature Highlights